Saliva Collection And Diagnostics Market Size, Share | Report 2022-2030
The global saliva collection and diagnostics market size was estimated at around USD 804.81 million in 2021 and it is projected to hit around USD 1.81 billion by 2030, growing at a CAGR of 9.42% from 2022 to 2030.
Report Highlights
The growing need to diagnose COVID-19-infected symptomatic and asymptomatic patients have created significant opportunities for the market. In August 2022, a research study published in PLOS ONE stated that oral fluid samples could be used for various diagnostic assays, such as COVID-19, due to its storage and ease of sample collection. Moreover, researchers have also stated that even if the salivary samples were stored for more than 28 days, it would remain reliable and useful.
Furthermore, the global burden of cancer and related deaths rose in 2020, majorly because of the increasing aging population and socioeconomic development. In April 2020, an article published in the American Society of clinical oncology stated that more than 50% of cancers globally are diagnosed in people aged 65 and older. Therefore, the saliva-based test is considered to be the best non-invasive procedure to detect cancer. In August 2022, OrisDX announced of developing a saliva-based non-invasive molecular test to diagnose and detect oral cancer at an early stage which would help in improving patient outcomes.
There has been significant growth in the adoption of saliva samples for both clinical and research applications as it offers non-invasive sampling, easy, simple collection, and higher patient compliance, among others. Several advancements and developments are happening in saliva specimens which would advance the proteomics field. For instance, in September 2022, an article published in India Today stated that researchers from IIT Roorkee identified salivary proteins which could help in predicting metastatic triple-negative breast cancer.
Key players operating in the market are taking several initiatives such as entering into strategic alliances and launching new products which are contributing to the overall growth. For instance, in January 2021, OraSure Technologies, Inc. announced that its saliva collection device, OMNIgene·ORAL, has been selected by Chronomics Limited for the SARS CoV-2 PCR test. Similarly, in August 2020, Fluidigm Corporation announced receiving FDA authorization for its saliva-based test, Advanta Dx SARS-CoV-2 RT-PCR assay. This test would help to detect the presence of coronavirus in the sample.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 804.81 million |
| Revenue Forecast by 2030 | USD 1.81 billion |
| Growth rate from 2022 to 2030 | CAGR of 9.42% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Site of collection, application, end-use, region |
| Companies Covered |
Thermo Fisher Scientific Inc.; Neogen Corporation; Abbott; Sarstedt AG & Co.KG; Autogen, Inc.; Oasis Diagnostics; Porex; Salimetrics, LLC; Takara Bio Inc.; Arcis Bio; Orasure Technologies |
Site Of Collection Insights
The submandibular/sublingual gland collection segment captured the highest revenue share of 48.76% in 2021 and is anticipated to continue to dominate during the forecast period. Approximately 70.0% of unstimulated saliva is produced in the submandibular gland. The most prevalent condition affecting the salivary glands in middle-aged adults is known as sialoliths or salivary stones. Approximately 80% of salivary sialoliths develop in the submandibular gland, followed by the parotid gland accounting for 6–15% and 2% in the minor or sublingual salivary glands. The increasing cases of sialolithiasis may contribute to the segment’s growth in the coming years.
The parotid gland collection segment is anticipated to witness considerable growth in the coming years. Salivary gland cancer is a rare malignancy that develops in the tissue of the salivary gland. Signs of this cancer include trouble swallowing or a lump. Majority of the salivary gland cancers are benign and occur in the parotid glands. This condition is evaluated by imaging tests or biopsies, such as CT scan, MRI, and positron emission tomography scans. The increasing incidence of parotid cancer has contributed to the segment’s saliva collection and diagnostics market growth.
Application Insights
The disease diagnostics segment captured the highest market share of 50.43% in 2021, owing to the increasing prevalence of diseases globally along with the increasing need for the proper diagnostic approach. According to the data published by CDC, in 2019, there were 8,916 new cases of tuberculosis, 58,371 cases of salmonella, 34,945 cases of Lyme disease, and 371 cases of meningococcal disease. Moreover, the saliva collection method is been used for the mass COVID-19 screening which is also one of the factors driving the growth of the segment.
The research segment is anticipated to witness significant growth in the coming years due to increased funding by public and private market players and the government in the R&D sector. Compared to conventional biofluids such as blood, oral biofluids holds significant potential for diagnostic testing. For instance, in September 2022, researchers from the Yale School of Public Health, Australia stated that saliva-based testing is useful for SARS-CoV-2 detection. Similarly, in October 2022, researchers from Ahmedabad University discovered miRNA in a human saliva sample, which shows promising results to predict the prognosis of oral cancer.
End-use Insights
The diagnostic laboratories segment dominated the market and accounted for the largest revenue share of 43.07% in 2021, owing to the presence of a higher number of diagnostics labs and chains globally to meet the growing needs of customers, thus driving the segment's growth. For instance, in February 2021, Eurofins Scientific launched an ultra-fast extraction-free RT-PCR technique to be used with a saliva sample and pharynx gargle matrices. Similarly, in October 2020, Synlab International GmbH announced the successful authentication of saliva sampling, a non-invasive sampling procedure for RT-PCR testing for SARS-CoV-2 detection.
The pharmaceuticals and biotechnology companies are projected to witness lucrative growth owing to several product launches and strategic alliances by the key market players. For instance, in September 2021, EQL Pharma launched a saliva-based Covid-19 antigen self-test. This is the first CE-marked test sold directly to customers rather than healthcare professionals. Similarly, in July 2021, Nusantics Group and Bio Farma launched the Bio Saliva test which could detect the presence of coronavirus in patients with or without symptoms using the gargling method.
Regional Insights
North America captured the highest market share of 42.59% in 2021 owing to increasing preference for saliva tests, the rising cases of infectious diseases, and the launch of novel products by the market players operating in the region. According to the data published by the American Cancer Society, in 2022, the U.S. to witness an estimated 54,000 new cases of oropharyngeal cancer or oral cavity, accounting for 11, 230 deaths. Furthermore, according to the data published by CDC, approximately 9 million new cases are to be registered in 2022, accounting for approximately 20,000 flu-related deaths. The growing burden of infectious diseases is creating significant demand for saliva collection and diagnostics, therefore, creating significant opportunities in the region.
Asia Pacific region is anticipated to witness the fastest growth rate owing to the significant advancements in the diagnostic testing field. According to a recent study published in April 2022, India witnessed a huge adoption of home-diagnostic tests and the trend is expected to increase in the coming years. People are adopting home-based diagnostic testing as it offers quick results at a lower cost. These factors have fueled the demand for saliva-based testing in the region.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Saliva Collection And Diagnostics Market
5.1. COVID-19 Landscape: Saliva Collection And Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Saliva Collection And Diagnostics Market, By Site of Collection
8.1. Saliva Collection And Diagnostics Market, by Site of Collection, 2022-2030
8.1.1 Parotid Gland Collection
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Submandibular/Sublingual Gland Collection
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Saliva Collection And Diagnostics Market, By Application
9.1. Saliva Collection And Diagnostics Market, by Application, 2022-2030
9.1.1. Disease Diagnostics
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Forensic Applications
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Research
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Saliva Collection And Diagnostics Market, By End-use
10.1. Saliva Collection And Diagnostics Market, by End-use, 2022-2030
10.1.1. Dentistry
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diagnostic Laboratories
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Pharmaceutical & Biotechnology Companies
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Research Institutes
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Saliva Collection And Diagnostics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Site of Collection (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Neogen Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sarstedt AG & Co.KG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Autogen, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Oasis Diagnostics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Porex
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Salimetrics, LLC
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Takara Bio, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Arcis Bio
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers